

Immuno-Struggle of *Trichomonas Vaginalis* to Live in the Human Body

Mohamed FAM*

Fayuom University, Faculty of medicine, Medical Parasitology Department, 63514, Fayuom, Egypt

***Corresponding author:** Faten Ahmed Mahmoud Mohamed, Fayuom University, Faculty of medicine, Medical Parasitology Department, 63514, Fayuom, Egypt,

Email: fam02@fayoum.edu.eg

Mini Review

Volume 1 Issue 4

Received Date: October 02, 2017

Published Date: October 10, 2017

Abstract

Trichomonas vaginalis is a urogenital flagellate, the etiological agent of human trichomoniasis. It is a worldwide curable sexually transmitted infection. It is often passed on by an asymptomatic carrier. *Trichomonas* induce pro-inflammatory and immunosuppressive cytokines in infected subjects. The parasite has also different immune evasion mechanisms to establish infection.

Keywords: *Trichomonas vaginalis*; Flagellate; Trichomoniasis; Immune Evasion

Introduction

Trichomonas vaginalis is a flagellated protist belonging to the Parabasalia that causes human trichomoniasis [1]. It is the third most common vaginal infection with an estimated incidence of 248 million new cases per year [2]. The infection occurs in the female and male urogenital tract and humans are the only natural host for the parasite [3]. It is principally spread via unprotected intercourse with an infected partner [1].

In women, the disease is ranging from asymptomatic state to severe inflammation [4]. In infected female patients, symptoms include: vaginal discharge, vulvar pruritis, dysuria, and dyspareunia. Classical green, frothy, foul-smelling discharge occurs in 10% of the women, and the red granular 'strawberry' cervix can be identified by the naked eye in less than 2% of patients [5].

Moreover, re-infection may occur by sexual contact with the man who acts as an asymptomatic carrier [6].

This significant heterogeneity in the clinical manifestations is due to genetic variability among *Trichomonas* isolates and the host immune response [7].

Complications of *T. vaginalis* infection can occur in untreated women and include endometritis, infertility [8] and cervical erosion [9]. Other complications caused by *T. vaginalis* include atypical pelvic inflammatory disease, prolonged carriage of human papilloma virus [10]. It also increases the risk of cervical cancer [11]. Its complications in pregnant women include: post abortion infection, post cesarean infection, low birth weight infants preterm labor and premature rupture of the membranes [12]. Untreated *T. vaginalis* infection in men could lead to chronic prostatitis, urethral strictures, epididymitis and/or infertility [13]. This infection increases the predisposition to human immunodeficiency virus (HIV) sero-conversion [14].

Host Immune Reaction

Minimal data exist to detail the human immune response to infection with *T. vaginalis*. The natural infection of *T. vaginalis* seems to produce immunity that is only partially protective [11]. Infection with *T. vaginalis* elicits cellular, humoral and secretory immune responses. However, these responses do not protect patients against re-infection, so repeated infections in women are commonly encountered in clinical settings [9]. The Innate immunity is an important first response by the host. Trophozoites attach to different mucosal surfaces of the lower urogenital tract and they are able to survive for long periods of time in the environment despite adverse conditions, such as acidic pH, and a robust immune response [11]. The vaginal epithelial cells are the first physical barrier that produces antimicrobial molecules and cytokines that can recruit other innate immune effector cells [15].

The cell surface lipophosphoglycan triggers parasite-specific immunoglobulin G (IgG), IgA, cytokines, leukotrienes and reactive nitrogen intermediates. It also induces nitric oxide synthase; priming of helper T cells and promotes transmigration of neutrophils across the endothelium [16].

IL-8 is a major chemokine responsible for neutrophil recruitment to sites of tissue insult and aggravation of the vaginal inflammation seen in symptomatic patient. IL-8 produced by monocytes and neutrophils stimulated by live trophozoites or undefined *T. vaginalis* membrane fragments [7]. These explain the abundance of neutrophils on wet mounts [17].

The host cells produce specific immunoglobulins (IgG and IgA) as a response to parasite antigens. This response may protect target cells from parasite-mediated cytotoxicity. However, there is a little evidence that such antibodies contribute to parasite clearance. Furthermore, persistent *T. vaginalis* infections suggest that humoral immune responses are not broadly protective [18].

Antibodies and complement components, present in serum and genital fluids of some individuals with trichomoniasis, can bind the surface of *T. vaginalis* and lyse them. They stimulate the neutrophil respiratory burst facilitating parasite killing via classical and alternative complement pathways [19].

Immune Evasion

Additionally, *T. vaginalis* has the ability to evade the host's immune system through complement mediated

destruction, molecular mimicry [16]. *T. vaginalis* can coat itself with host plasma proteins. Thus, the host immune system does not recognize the parasite as foreign. This parasite also secretes copious amounts of highly immunogenic soluble antigens in a continuous way to neutralize antibody or cytotoxic T lymphocytes [20].

Moreover, *T. vaginalis* produces immuno-suppressive cytokines (as IL-10) which causes caspase-mediated apoptosis in T-cells, macrophages and dendritic cells [21]. Cytotoxic effects of macrophages on *T. vaginalis* have an important role in host innate immunity, but it is reported that *T. vaginalis* inhibits pro-inflammatory cytokine production in macrophages to evade the immune system [22]. Another evasion way is phenotypic variation mechanism which detect by expression or non-expression of 270kDa protein. *T. vaginalis* are described as positive or negative P270. *T. vaginalis* which is positive cannot express protein hence doesn't have the ability of adhesion [23]. The role of the human immune system in trichomoniasis is important in order to develop targeted intervention strategies to control the disease.

References

1. Chalechale A, Karimi I (2010) The prevalence of *T. vaginalis* infection among patients that presented to hospitals in the Kermanshah district of Iran in 2006 and 2007. *Turk J Med Sci* 40(6): 971-975.
2. WHO (2012) Global incidence and prevalence of selected curable sexually transmitted infections: 2008. World Health Organization 20.
3. Maritz JM, Land KM, Carlton JM, Hirt RP (2014) What is the importance of zoonotic trichomonads for human health? *Trends Parasitol* 30(7): 333-341.
4. Fichorova RN, Trifonova RT, Gilbert RO, Costello CE, Hayes GR, et al. (2006) *T. vaginalis* lipophosphoglycan triggers a selective upregulation of cytokines by human female reproductive tract epithelial cells. *Infect Immun* 74(10): 5773-5779.
5. Loo S, Tang WYM, Lo KK (2009) Clinical significance of *T. vaginalis* detected in Papanicolaou smear: a survey in female social hygiene clinic. *Hong Kong Med J* 15 (2): 90-93.
6. Perazzi BE, Menghi CI, Coppolillo EF, Gatta C, Eliseth MC, et al. (2010) Prevalence and comparison of diagnostic methods for *T. vaginalis* infection in pregnant women in Argentina. *Korean J Parasitol* 48(1): 61-65.

7. Mairiga AG, Balla H, Ahmad MI (2011) Prevalence of *T. vaginalis* infections among antenatal clients in Maiduguri Nigeria. *Int J Biol Med Res* 2(4): 998-1002.
8. El-Shazly AM, El-Naggar HM, Soliman M, El-Negeri M, El-Nemr HE, et al. (2001) A study on Trichomoniasis vaginalis and female infertility. *J Egypt Soc Parasitol* 31(2): 545-553.
9. Petrin D, Delgaty K, Bhatt R, Garber G (1998): Clinical and microbiological aspects of *Trichomonas vaginalis*. *Clin Microbiol Rev* 11(2): 300-317.
10. Andrea SB, Chapin KC (2011) Comparison of aptima *T. vaginalis* transcription-mediated amplification assay and BD Affirm VPIII for detection of *T. vaginalis* in symptomatic women: Performance parameters and epidemiological implications. *Clin Microbiol* 49(3): 866-869.
11. Harp DF, Chowdhury I (2011) Trichomoniasis: evaluation to execution. *Eur J Obstet Gynecol Reprod Biol* 157(1): 3-9.
12. Housou Y, Farraj MA, Ramlawi A, Essawi T (2011) Detection of *T. vaginalis* in vaginal swab clinical samples from Palestinian women by culture. *ISRN Microbiol* 1-4.
13. Caliendo AM, Jordan JA, Green AM, Ingersoll J, Diclemente RJ, et al. (2005) Real-time PCR improves detection of *T. vaginalis* infection compared with culture using self-collected vaginal swabs. *Infect Dis Obstet Gynecol* 13(3): 145-150.
14. Guenther PC, Secor WE, Dezzutti CS (2005) *Trichomonas vaginalis* induced epithelial monolayer disruption and human immunodeficiency virus type-1 (HIV-1) replication: implications for the sexual transmission of HIV-1. *Infection and Immunity* 73(7): 4155-4160.
15. Okumura CY, Baum LG, Johnson PJ (2008) Galectin-1 on cervical epithelial cells is a receptor for the sexually transmitted human parasite *T. vaginalis*. *Cell Microbiol* 10(10): 2078-2090.
16. Singh BN, Hayes GR, Lucas JJ, Sommer U, Viseux N, et al. (2009) Structural details and composition of *Trichomonas vaginalis* lipophosphoglycan in relevance to the epithelial immune function. *Glycoconj J* 26(1): 3-17.
17. Ryu JS, Kang J-H, Jung S-Y, Shin M-H, Kim J-M, et al. (2004) Production of interleukin-8 by human neutrophils stimulated with *Trichomonas vaginalis*. *Infect Immun* 72(3): 1326-1332.
18. Lubick KJ, Burgess DE (2004) Purification and analysis of phospholipase A2 like lytic factor of *Trichomonas vaginalis*. *Infect Immun* 72(3): 1284-1290.
19. Holmes K, Sparling P, Stamm WE, Piot P, Wasserheit JN, et al. (2008) Sexually transmitted Protozoa, Fungi, and Ecto-parasites: *Trichomonas vaginalis* and trichomoniasis. In: *sexually transmitted diseases*, 4th (Edn.) New York: McGraw-Hill 772-793.
20. Malla N (2012) Human trichomoniasis due to *T. vaginalis*, Current perspectives. *Sex transmit infect In Tech* 107-123.
21. Fichorova N (2009) Impact of *T. vaginalis* infection on innate immune responses and reproductive outcome. *Reprod Immunol J* 83(1-2): 185-189.
22. Chang JH, Ryang YS, Morio T, Lee SK, Chang EJ (2004) *Trichomonas vaginalis* inhibits pro-inflammatory cytokine production in macrophages by suppressing NF- κ B activation. *Mol Cells* 18(2): 177-185.
23. Khoshnan A, Alderete JF (1994) *Trichomonas vaginalis* with a double-stranded RNA virus has upregulated levels of phenotypically variable immunogen mRNA *Virology* 68(6): 4035-4038.